CSBR · XBRL financial data

Champions Oncology financial statements, every fiscal year

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CSBR's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Revenue from contracts with customers	41,040	49,109	53,870	50,155	56,944	59,425
Cost of goods and services sold	21,446	23,632	29,532	29,401	28,389	30,900
Research and development	7,196	9,374	11,545	9,544	6,825	9,084
General and administrative	6,512	9,117	10,240	11,067	9,339	11,152
Operating income (loss)	366	607	(5,256)	(7,356)	4,553	(1,140)
Other income (expense)	71	(24)	(11)	48	73	211
Income tax expense (benefit)	75	35	68	(32)	(75)	246
Net income (loss)	362	548	(5,335)	(7,276)	4,701	(1,175)
Earnings per share, basic USD per share	0.03	0.04	(0.39)	(0.54)	0.34	(0.08)
Earnings per share, diluted USD per share	0.02	0.04	(0.39)	(0.54)	0.33	(0.08)
Weighted average shares, basic thousands of shares	13,139	13,197	13,542	13,548	13,660	13,832
Weighted average shares, diluted thousands of shares	14,574	14,160	13,542	13,548	14,267	13,832

Fiscal years (CSBR's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Cash and cash equivalents	4,687	9,007	10,118	2,618	9,785	4,872
Accounts receivable	6,986	9,513	8,011	9,526	11,234	13,178
Prepaid and other current assets	957	1,144	1,328	1,495	1,350	1,169
Total current assets	12,630	19,664	19,457	13,639	22,369	19,219
Property and equipment, net	6,090	7,134	—	—	—	—
Right-of-use asset	8,521	8,230	7,318	6,252	5,080	3,697
Goodwill	335	335	335	335	335	335
Total assets	27,591	35,378	34,311	26,132	32,344	26,989
Accounts payable	1,894	2,868	5,334	5,800	4,248	6,903
Accrued liabilities	2,231	2,414	2,270	2,160	2,556	2,592
Total current liabilities	11,199	17,479	21,733	21,541	23,853	19,922
Lease liability, non-current	8,783	8,412	7,391	6,093	4,634	2,992
Total liabilities	20,163	26,282	29,675	28,035	28,572	22,921
Accumulated deficit	(72,530)	(71,982)	(77,317)	(84,593)	(79,892)	(81,067)
Total stockholders' equity	7,428	9,096	4,636	(1,903)	3,772	3,939
Total liabilities and equity	27,591	35,378	34,311	26,132	32,344	26,989
Common shares outstanding (cover page) thousands of shares	13,415	13,522	13,460	13,594	13,777	13,894

Fiscal years (CSBR's year ends in late April)

In thousands of dollars	FY 2021Apr 30, 2021	FY 2022Apr 30, 2022	FY 2023Apr 30, 2023	FY 2024Apr 30, 2024	FY 2025Apr 30, 2025	FY 2026Apr 30, 2026
Net income (loss)	362	548	(5,335)	(7,276)	4,701	(1,175)
Stock-based compensation	598	912	864	1,118	654	1,237
Depreciation and amortization	1,200	1,500	2,100	1,700	1,600	1,400
Net cash from operating activities	(1,681)	6,497	3,972	(6,137)	7,386	(4,472)
Purchases of property and equipment	3,281	2,384	2,872	836	389	564
Net cash from investing activities	(3,169)	(2,384)	(2,872)	(836)	(389)	(540)
Share repurchases	—	0	74	634	0	—
Net cash from financing activities	1,195	207	11	(527)	170	99
Net change in cash	(3,655)	4,320	1,111	(7,500)	7,167	(4,913)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Champions Oncology	4,358	15,232	(492)	13.9M	8.0 quarters	Q1 FY27 10-QJul 31, 2026
Rockwell Medical	10,519	not reported	2,080*	4.0M	—	Q2 FY26 10-QJun 30, 2026
OnKure Therapeutics	166,502	not reported	(10,354)*	40.5M	17.0 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026
ProMIS Neurosciences	53,429	not reported	(10,385)*	9.0M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Tempest Therapeutics	779	not reported	(2,779)*	16.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Outlook Therapeutics	11,242	not reported	(21,011)*	243.4M	0.5 quarters	Q3 FY26 10-QJun 30, 2026
Provectus Biopharmaceuticals	1,157	not reported	(358)*	420.3M	3.2 quarters	Q2 FY26 10-QJun 30, 2026
Palatin Technologies	7,492	301*	(2,690)*	1.8M	2.8 quarters	Q4 FY26 10-KJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.